For the Inventor, By the Inventor

Enter inventor name

Ventura, CA, United States of America

Robert Michael Rzasa

USPTO Granted Patents = 38 (Patent Applications = 9)

CIPO Patents = 2

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 9.7

ph-index = 7

Forward Citations = 261(Granted Patents)

Location History:

Thousand Oaks, CA (US) (2015 - 2017)
Ventura, CA (US) (2004 - 2018)

Company Filing History:

38 out of 1,970

Years Active: 2004-2018

where 'Filed Patents' based on already Granted Patents

38 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9873701 - Heterocyclic compounds and their uses (2018-01-23),

2. 9718803 - Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors (2017-08-01),

3. 9611261 - Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-04-04),

4. 9556135 - Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use (2017-01-31),

5. 9550762 - Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-01-24),

6. 9493459 - Azetidine and piperidine compounds useful as PDE10 inhibitors (2016-11-15),

7. 9376450 - Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors (2016-06-28),

8. 9303028 - Azetidine and piperidine compounds useful as PDE10 inhibitors (2016-04-05),

9. 9296734 - Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2016-03-29),

10. 9174992 - Heterobicyclic compounds (2015-11-03),

11. 9090593 - Bicyclic compounds as Pim inhibitors (2015-07-28),

12. 9085576 - Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2015-07-21),

13. 8957073 - Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors (2015-02-17),

14. 8952037 - Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors (2015-02-10),

15. 8946230 - Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors (2015-02-03),

Title: Robert Michael Rzasa: Innovator in Pharmaceutical Patents

Introduction

Robert Michael Rzasa, located in Ventura, California, is an accomplished inventor with an impressive portfolio of 38 patents. His work primarily focuses on the development of novel compounds geared towards treating various inflammatory diseases, cancers, and other complex medical conditions.

Latest Patents

Among his latest innovations, Rzasa has developed patents for heterocyclic compounds and their applications in treating general inflammation, arthritis, and various autoimmune diseases. His inventions encompass a range of conditions, including osteoarthritis, inflammatory bowel disorders, and chronic inflammatory conditions, as well as allergic conditions. Notably, Rzasa’s work also addresses cancers associated with p110δ activity, such as different forms of leukemia and solid tumors, including breast cancer. Additionally, he has made significant contributions with unsaturated nitrogen heterocyclic compounds classified as PDE10 inhibitors, which are useful in treating disorders such as Huntington's disease, schizophrenia, and bipolar disorder.

Career Highlights

Robert Michael Rzasa plays a pivotal role at Amgen Inc., a leading biopharmaceutical company dedicated to developing innovative therapies. His extensive experience and contributions in the field of pharmaceutical patents highlight his commitment to advancing healthcare through groundbreaking research and development.

Collaborations

Throughout his career, Rzasa has collaborated with several distinguished professionals, including Jennifer Rebecca Allen and Andreas Reichelt. These partnerships have allowed him to enhance his research and foster an environment of innovation within the pharmaceutical field.

Conclusion

Robert Michael Rzasa is a notable figure in the world of pharmaceuticals, exemplifying the integration of science and innovation to address critical health issues. With his significant number of patents and continued contributions to medical research, Rzasa remains a key player in developing therapies that improve patient outcomes and enhance the quality of life for many individuals.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…